European Archives - Page 340 of 1157 - European Medical Journal

Scoring System Predicts Need for Intervention for Non-Muscle Invasive Bladder Cancer Patients

Patients with low-grade (LG) Ta non-muscle invasive bladder cancer (NMIBC) exhibit a high recurrence rate, while cancer-specific…

Twenty-Year Follow-Up of Large-Volume Low-Grade Urothelial Carcinoma

According to the European Association of Urology (EAU) Guidelines, tumour size exceeding 2 cm serves as a crucial factor…

Buccal Mucosa Graft Urethroplasty With or Without Meatus Reconstruction

Approximately 15–20% of patients who undergo urethroplasty (UP) with buccal mucosa graft (BMG) will suffer urethral stricture recurrence…

EAU 2024 Abstract Highlights

PROSTATE-specific membrane antigen (PSMA)-PET imaging can influence decision-making in prostate cancer, improving survival outcomes…

NOTION-2 Trial: Breaking News from EuroPCR 2024

The NOTION-2 trial is a pivotal study that focused on low surgical risk patients aged 75 years or younger, including both tricuspid and bicuspid aortic stenosis (AS) cases…

REC-CAGEFREE II Trial: Breaking News from EuroPCR 2024

Results of the REC-CAGEFREE II trial were presented today at EuroPCR by Ling Tao, FAHA Xijing hospital, Xi’an, China on behalf all REC-CAGEFREE II investigators….

Extended Lymphadenectomy Lacks Benefits for Urothelial Cancer

A recent subgroup analysis has provided crucial insights into the safety of extended lymph node dissection.

D-Mannose Ineffective in Reducing Recurrent Urinary Tract Infections

A randomised clinical trial has found that D-mannose does not live up to its promise.

Catheter-Based Renal Artery Denervation

This infographic explores the advantages and disadvantages of catheter-based renal artery denervation, with key insights into resistant…

Transcatheter Valve and Vessels Trial: Breaking News from EuroPCR 2024

The Transcatheter Valve and Vessels (TCW) Trial, the first dedicated randomised, international study in patients with both aortic stenosis and advanced coronary disease, has delivered new insights…